Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S14 & S15 NDA 21-039/S13 & S14 10/2/02 10/11/01 10/3/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S11 NDA 21-039/S10 8/2/02 8/6/02 8/5/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S10, & 13 NDA 21-039/S9 & 12 2/5/02 4/17/02 Agenerase (amprenavir) Capsules and Solution, 50mg, 150mg Glaxo Wellcome NDA 21-007 NDA 21-039 4/15/99 7/24/02 5/25/99 7/24/02 Agenerase Indication: for the treatment of HIV-1 infection. Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S6 NDA 21-039/S6 Agenerase (amprenavir) Capsules and Oral Solution, GlaxoSmithKline

For the most up-to-date approval information, please locate this API using the drug index.